# Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM

> **NCT06503107** · PHASE1,PHASE2 · RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 60 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Nanobody-based biepitope BCMA-targeting CAR-T cells

## Key facts

- **NCT ID:** NCT06503107
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-23
- **Primary completion:** 2026-04-18
- **Final completion:** 2026-10-18
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-07-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06503107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06503107, "Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06503107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*